Deadliest Cancer Stumbles — Pill Doubles Survival Rate

A doctor's gloved hand placing red blocks with health symbols on a table

A daily pill just doubled survival time for one of the deadliest cancers on earth — and the crowd of oncologists who heard the news gave it a standing ovation.

Quick Take

A new drug called daraxonrasib nearly doubled survival in advanced pancreatic cancer patients — from 6.7 months to 13.2 months — compared to standard chemotherapy.
The drug targets a gene mutation called RAS, which drives more than 90% of all pancreatic cancers and was considered “undruggable” for decades.
Separately, lab scientists discovered a compound that forces pancreatic cancer cells to self-destruct by overloading their own internal systems — a completely different attack strategy.
Neither approach is a cure yet, but together they signal a genuine turning point in a disease that has resisted nearly every treatment for 50 years.

Why Pancreatic Cancer Has Been So Hard to Beat

Pancreatic cancer kills roughly 88% of patients within five years of diagnosis. That number has barely budged in half a century. The reason is brutal and simple: the cancer hides behind a thick wall of fibrous tissue, resists chemotherapy, and spreads before most patients feel a single symptom. At its core, the disease is powered by a mutated gene called RAS — a molecular switch stuck permanently in the “on” position, telling cells to grow without stopping.

For 40 years, researchers tried to block RAS and failed every time. The protein’s surface offered no good place for a drug to grab hold. Scientists eventually labeled it “undruggable” and moved on. That label just got torn up.

The Drug That Drew a Standing Ovation

Daraxonrasib, developed by Revolution Medicines, is the first oral drug designed to block multiple RAS mutations at once. In May 2026, researchers presented results from the RASolute 302 Phase 3 trial at the American Society of Clinical Oncology (ASCO) annual meeting. The audience of cancer specialists stood and applauded. That almost never happens at a medical conference.

The trial enrolled 500 patients with metastatic pancreatic cancer whose disease had already stopped responding to first-line chemotherapy. Patients on daraxonrasib survived a median of 13.2 months, compared to 6.7 months for those on standard chemotherapy — a 60% reduction in the risk of death. Tumors shrank in about one-third of patients on the drug, versus roughly 11% on chemotherapy. Perhaps just as striking: only 1.2% of patients on daraxonrasib stopped treatment because of side effects, compared to 11.2% on chemotherapy. The most common complaints were rash, mouth soreness, nausea, and diarrhea — real issues, but manageable ones.^[1]^[2]

What Makes This Drug Different From Past Attempts

Earlier RAS-targeting drugs only worked on one specific mutation — a variant called KRAS G12C — found in only a small slice of pancreatic cancer patients. Daraxonrasib targets multiple RAS mutations, including the G12 family that drives the vast majority of cases. It works by locking RAS in its inactive state, starving the cancer of the signal it needs to grow. At six months into the trial, 84% of patients showed no disease progression and 90% were still alive. Those numbers are extraordinary for this disease.^[3]

A Second Front: Making Cancer Cells Destroy Themselves

While daraxonrasib was making headlines, a separate team of lab scientists published a very different discovery. Researchers found a class of experimental compounds — including one called NSL-YHJ-2-27 — that attack pancreatic cancer cells through a counterintuitive strategy. Instead of blocking cancer signals, these compounds flood the cancer cell’s internal pathways until the cell essentially overloads and self-destructs. In lab tests, the compound blocked more than 90% of cancer cell migration at a very low dose. This approach is still in early pre-clinical stages — tested in cell cultures and mouse models, not humans — but the mechanism is genuinely novel.^[8]

It is worth being clear-eyed here. Pre-clinical results in mice frequently fail to translate into human benefits. The researchers themselves stated that more trials are needed before anyone knows if this strategy is safe or effective in people. Still, the underlying idea — tricking cancer into killing itself — is a legitimate and creative direction that complements the RAS-blocking approach rather than competing with it.

Real Hope, Real Limits

Daraxonrasib is not yet approved by the Food and Drug Administration (FDA). Revolution Medicines has applied for approval, and the FDA has granted expanded access, meaning some patients can get the drug before the formal green light. Resistance remains a serious problem — no drug in this class has produced long-term survivors in pre-clinical models when used alone. Researchers are already running trials combining daraxonrasib with other agents, including immune therapies and a drug called TNG462, hoping that combination attacks will prevent the cancer from adapting and escaping.^[3]

Pancreatic cancer has broken the hearts of researchers and patients for generations. What is different now is the convergence of multiple credible strategies arriving at roughly the same time — a targeted oral pill that doubled survival in a rigorous trial, a lab compound with a brand-new mechanism, and a pipeline of combination therapies designed to close the escape routes cancer uses to survive. None of this is a cure. All of it is real progress. For a disease that offered almost nothing for decades, that distinction matters enormously.